A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is an open-label, randomized, positive drug-controlled Phase Ⅱ clinical study to compare the efficacy and safety of HB1801 to Taxotere in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed platinum- containing chemotherapies.
Epistemonikos ID: c233b8bf16372785aef5a08ca70cebe3a67be4ac
First added on: Feb 19, 2024